abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English


14 Aug 2006

Interfaith Center on Corporate Responsibility - new report on pharmaceutical firms' responses to AIDS

In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets".  A PowerPoint summary of the report, which includes scores and "bottom line" assessment of each company, is available here.  The Business & Human Rights Resource Centre invited the 15 benchmarked companies to respond to the report; the results to date are indicated below.  Below the companies' responses are rejoinders by ICCR and Physicians for Social Justice (Nigeria) to the companies' responses, and a November 2006 follow-up report by ICCR.


Abbott Laboratories statement [DOC]

AstraZeneca response [DOC]

Boehringer-Ingelheim response [DOC]

Bristol-Myers Squibb response [DOC]

Eli Lilly - declined to respond

Gilead Sciences - declined to respond

GlaxoSmithKline response [DOC]

Hoffman-La Roche - declined to respond

Merck response [PDF]

Novartis response [DOC]

Pfizer response [PDF]

sanofi-aventis - declined to respond

Schering-Plough - declined to respond

Tibotec (part of Johnson & Johnson) response [DOC]

Wyeth - press release sent in response to ICCR report


ICCR statement regarding the company responses (6 Nov 2006) [DOC]

Physicians for Social Justice (Nigeria) rejoinder to the company responses [DOC]
Novartis response to Physicians for Social Justice [DOC]


Benchmarking AIDS: 2006 Year End Update [PDF]
- includes recent steps taken by Abbott, Gilead, GlaxoSmithKline, Novartis, Roche & recommendations for next steps for each of these companies


AstraZeneca Antwort anzeigen
Boehringer Ingelheim Antwort anzeigen
Bristol-Myers Squibb Antwort anzeigen
Eli Lilly

Keine Antwort

Gilead Sciences

Keine Antwort

Hoffmann-La Roche (part of Roche)

Keine Antwort

Novartis Antwort anzeigen

Keine Antwort


Keine Antwort


Keine Antwort

Wyeth (part of Pfizer) Antwort anzeigen